E
Emergence Therapeutics
Biotech & Life Sciences · Duisburg, Germany · Founded 2019
European biopharmaceutical company developing novel ADC immuno-therapeutics to treat high-unmet need cancers MoreLess
Emergence Therapeutics is a biotechnology company focused on developing Antibody-Drug Conjugates (ADCs) for the treatment of hard-to-treat cancers. The company's lead program, ETx 22, targets Nectin 4 and aims to deliver higher efficacy with lower risk of off-target side effects and the ability to avoid tumor resistance. ETx 22 utilizes an innovative linker and payload technology to achieve these goals. Emergence Therapeutics serves patients with difficult-to-treat cancers and operates in the biopharmaceutical market. The business model revolves around the development and commercialization of first or best-in-class ADCs, driven by therapeutic need. Revenue is generated through the development and potential future sales of these ADCs, as well as possible partnerships and licensing agreements.
Keywords: ADCs, Nectin 4, cancer treatment, biotechnology, biopharmaceutical, tumor resistance, innovative technology, therapeutic need, commercialization, partnerships.
Company overview
Emergence Therapeutics company information
The essential company record, classifications and operating signals in one place.
- Status
- Acquired
- Founded
- 2019
- Headquarters
- Duisburg, Germany
- Employees
- 13
- Open positions
- None listed
- Dealroom signal
- 59.0
Valuation & funding
Emergence Therapeutics funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Jun 2023 | $0 | — | Eli Lilly | ↗ |
| SERIES AOther financing | Dec 2021 | $96M | $383M | Hadean Ventures · Gründerfonds Ruhr · Surveyor Capital · Pontifax Funds | ↗ |
| SEEDOther financing | Nov 2020 | — | — | HTGF · Eurazeo · NRW.BANK · Gründerfonds Ruhr | — |
| SPINOUTOther financing | Nov 2019 | $0 | — | Aix-Marseille University | — |
Growth signals
Emergence Therapeutics website traffic
Latest recorded traffic for Emergence Therapeutics is 310 monthly website visits, up 106.7% over the last three months. Emergence Therapeutics's team grew 0% over the past year.
Comparisons
Emergence Therapeutics compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Emergence Therapeutics's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Emergence Therapeutics has talent and traffic
In the news
Latest news about Emergence Therapeutics
Recent press, funding announcements, and product moves mentioning Emergence Therapeutics — open to read from the original sources.
Market sentiment
What the market is saying about Emergence Therapeutics
An AI-synthesized read of the highest-engagement posts about Emergence Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Emergence Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.